AstraZeneca settles one Seroquel XR patent dispute, many remain
This article was originally published in Scrip
Executive Summary
Intellipharmaceutics has reached an agreement with AstraZeneca to settle all outstanding patent litigation concerning its abbreviated new drug application (ANDA) for the commercialisation in the US of a generic version of the latter's atypical antipsychotic drug, Seroquel XR (quetiapine fumarate extended-release) tablets.